LIGAND PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

LGND$314.15+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except par value)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$22,954	$45,006
Short-term investments	147,355	166,864

LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts receivable, net	32,917	30,424
Inventory	23,969	13,294
Income taxes receivable	6,395	4,614
Prepaid expenses	1,182	1,132
Other current assets	2,657	2,267
Total current assets	237,429	263,601
Deferred income taxes, net	214	8,530
Intangible assets, net	299,606	342,455
Goodwill	103,370	105,673
Commercial license and other economic rights	67,291	10,182
Property and equipment, net	15,607	12,482
Operating lease assets	6,062	10,914
Finance lease assets	3,393	4,095
Equity method investment in Primrose Bio	12,595	—
Other investments	35,726	3,000
Other assets	5,923	1,736
Total assets	$787,216	$762,668
Current liabilities:
Accounts payable	$2,427	$5,307
Accrued liabilities	12,467	15,681
Current contingent liabilities	256	57
Deferred revenue	1,222	355
Current operating lease liabilities	403	670
Current finance lease liabilities	7	45
2023 convertible senior notes, net	—	76,695
Total current liabilities	16,782	98,810
Long-term deferred revenue	1,444	44
Long-term contingent liabilities	2,942	3,456
Deferred income taxes, net	31,622	30,615
Long-term operating lease liabilities	5,755	10,336
Other long-term liabilities	27,758	21,922
Total liabilities	86,303	165,183
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December 31, 2023 and 2022, respectively	18	17
Additional paid-in capital	198,696	147,590
Accumulated other comprehensive loss	(817)	(984)
Retained earnings	503,016	450,862
Total stockholders’ equity	700,913	597,485
Total liabilities and stockholders’ equity	$787,216	$762,668

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.